Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00070642 | CPG 7909 Injection in Melanoma | PHASE2 | COMPLETED | 184 | — | — | Dec 1, 2003 | Dec 1, 2005 | Feb 10, 2009 | - | — |
| Arm | Type | Description |
|---|---|---|
| CPG 7909 Injection plus chemotherapy | EXPERIMENTAL | CPG 7909 Injection plus DTIC |
| Chemotherapy alone | ACTIVE_COMPARATOR | dacarbazine |
| CPG 7909 Injection 10 mg | EXPERIMENTAL | - |
| CPG 7909 Injection 40 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CPG 7909 Injection | DRUG | CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly. |
| dacarbazine | DRUG | dacarbazine 850mg/m2 in three-week cycles until disease progression |
| Chemotherapy | DRUG | Chemotherapy in three-week cycles until disease progression: dacarbazine 850mg/m2 |
Inclusion Criteria: * Histologically or cytologically confirmed melanoma that is metastatic. * Measurable disease according to the RECIST criteria. * Karnofsky Performance Status of \> 70. Exclusion Criteria: * Prior treatment with anti-neoplastic biologic or chemotherapy for recurrent or metasta...